Publications by authors named "Nikita P Volkov"
Article Synopsis
- Dose-intensive therapies during allogeneic hematopoietic stem cell transplantation (allo-HSCT) significantly disrupt gut microbiota and promote antibiotic resistance, with recovery patterns poorly understood.
- In a study of 12 adult patients, stool samples revealed a marked decline in microbial diversity starting from day 0, persisting for up to a year, with specific bacterial genera showing slower recovery.
- A rise in antibiotic-resistant bacteria was observed around day 30 post-transplant, with resistance to major antibiotic classes, but a gradual decrease in resistance levels was noted over the following year.
Objectives: Therapy of patients with relapsed and refractory classic Hodgkin lymphoma (r/r cHL) after PD-1 inhibitors failure remains an unresolved issue. The aim of this study was to evaluate the efficacy and safety of the combination of nivolumab with brentuximab vedotin (Nivo + BV) after nivolumab monotherapy failure.
Methods: This study retrospectively analyzed 21 patients with r/r cHL who were treated with the combination of Nivo + BV after Nivo failure.
The introduction of nivolumab has changed the landscape of relapsed/refractory classical Hodgkin lymphoma (r/r cHL) treatment. Despite its clinical importance, this therapy may remain inaccessible for a significant number of patients worldwide, especially in low-income countries, due to its high cost. The results of pharmacokinetic analysis and clinical observations suggest the potential efficacy of low dose nivolumab in r/r cHL patients.
View Article and Find Full Text PDF